SARS-CoV2 vaccine and viral variant research library

Compiled by Dr. Steven Hatfill, MD, MMed, Erik Sass, et al. 

Doi: 10.5281/zenodo.14594436

Last updated January 3, 2025. Corresponding author: eriksass@gmail.com 

In addition to the pathogenicity, distribution, and long persistence of the “vaccine” spike protein (https://zenodo.org/records/14269255, https://zenodo.org/records/14559625), a growing body of research links COVID “vaccination” to the evolution of vaccine-resistant viral variants. The following collection of over 50 (n=63) peer-reviewed papers suggests the “vaccines” applied strong selective pressure to the fast-mutating SARS-CoV2 virus, quickly giving rise to “vaccine”-resistant variants. It is noteworthy that variants emerged in temporal and geographic proximity to “vaccine” clinical trials or mass “vaccination”:

1. The Alpha variant was first identified in the county of Kent in southeast England in November 2020. Phase I/II clinical trials for AstraZeneca’s AZD1222 (ChAdOx1 nCoV-19) adenovector “vaccine” enrolled over 1,000 subjects in southern England in April 2020, and thousands more in the phase III trial, May-December 2020.

2. The Delta variant was first identified in Maharashtra state, India, in October 2020. Phase II/III clinical trials for the Covidshield adenovector “vaccine” based on AstraZeneca’s AZD1222 enrolled 1,600 subjects at 14 hospital centers, including eight in Maharashtra state, from July-October 2020.

3. The Omicron variant was first identified in Gauteng, South Africa, in November 2021, following an intense provincial “vaccination” campaign from August-October.

 On this note, public health officials have warned that “chasing variants” is likely futile:

• In January 2023, Dr. Peter Marks, director of FDA’s Center for Biologics Evaluation and Research, wrote: “Continuing along the current path of…  variant-specific vaccine boosters is inadequate as a long-term strategy for addressing COVID-19... Simply updating the existing vaccine constructs with new variant sequences or even making trivalent or quadrivalent vaccines… is not likely to provide the depth and breadth of protection needed to interrupt viral transmission."
• FDA Vaccines and Related Biological Products Advisory Committee (VRBPAC) member Dr. Paul Offit told Time: “The experience of the past year has taught us that chasing these Omicron variants with a bivalent vaccine is a losing game.”

This compilation originated with Dr. Hatfill’s contribution to TOXIC SHOT: Facing the Dangers of the COVID "Vaccines." (Chapter 5: Debunking CDC’s Bad Science)

See also:

“SARS-CoV2 spike protein pathogenicity research collection” (n=320) https://zenodo.org/records/14559644

“mRNA ‘vaccine’ biodistribution, persistence, and adjuvant toxicity library” (n=130) https://zenodo.org/records/14559625

“COVID ‘vaccine’ immune imprinting library” (n=131) https://zenodo.org/records/14632346